<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38527615</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-0691</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>7</Issue><PubDate><Year>2024</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</Title><ISOAbbreviation>Clin Microbiol Infect</ISOAbbreviation></Journal><ArticleTitle>Prevalence of long COVID in the general adult population according to different definitions and sociodemographic and infection characteristics. A nationwide random sampling survey in France in autumn 2022.</ArticleTitle><Pagination><StartPage>924</StartPage><EndPage>929</EndPage><MedlinePgn>924-929</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cmi.2024.03.020</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1198-743X(24)00150-2</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Long COVID has been recognized since early 2020, but its definition is not unanimous, which complicates epidemiological assessments. This study estimated the prevalence of long COVID based on several definitions and severity thresholds in the adult population of mainland France and examined variations according to sociodemographic and infection characteristics.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A cross-sectional survey using random sampling was conducted in August-November 2022. Participants declaring SARS-CoV-2 infection were assessed for infection dates and context, post-COVID symptoms (from a list of 31, with onset time, daily functioning impact, and alternative diagnosis), and perceived long COVID. Long COVID prevalence was estimated according to the WHO, National Institute for Health and Care Excellence, United States National Centre for Health Statistics, and United Kingdom Office for National Statistics definitions.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 10&#xa0;615 participants, 5781 (54.5%) reported SARS-CoV-2 infection, with 123-759 (1.2-13.4%) having long COVID, depending on the definition. The prevalence of WHO post-COVID condition (PCC) was 4.0% (95% CI: 3.6-4.5) in the overall population and 8.0% (95% CI: 7.0-8.9) among infected individuals. Among the latter, the prevalence varied from 5.3% (men) to 14.9% (unemployed) and 18.6% (history of hospitalization for COVID-19). WHO-PCC overlapped poorly with other definitions (kappa ranging from 0.18 to 0.59) and perceived long COVID (reported in only 43% of WHO-PCC).</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Regardless of its definition, long COVID remains a significant burden in the French adult population that deserves surveillance, notably for forms that strongly impact daily activities. More standardized definitions will improve integrated surveillance of, and better research on, long COVID.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Coste</LastName><ForeName>Jo&#xeb;l</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Non-Communicable Diseases and Injuries, French Public Health Agency (Sant&#xe9; Publique France), Saint-Maurice, France. Electronic address: joel.coste@santepubliquefrance.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delpierre</LastName><ForeName>Cyrille</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>CERPOP, UMR 1295, Inserm Universit&#xe9; Toulouse III, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richard</LastName><ForeName>Jean-Baptiste</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Non-Communicable Diseases and Injuries, French Public Health Agency (Sant&#xe9; Publique France), Saint-Maurice, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alleaume</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Non-Communicable Diseases and Injuries, French Public Health Agency (Sant&#xe9; Publique France), Saint-Maurice, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallay</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Non-Communicable Diseases and Injuries, French Public Health Agency (Sant&#xe9; Publique France), Saint-Maurice, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tebeka</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Non-Communicable Diseases and Injuries, French Public Health Agency (Sant&#xe9; Publique France), Saint-Maurice, France; Universit&#xe9; Paris Cit&#xe9;, INSERM UMR1266, Institute of Psychiatry and Neurosciences, Team 1, Paris, France; Department of Psychiatry, AP-HP, Louis Mourier Hospital, Colombes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemogne</LastName><ForeName>C&#xe9;dric</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Paris Cit&#xe9; and Universit&#xe9; Sorbonne Paris Nord, Inserm, INRAE, Center for Research in Epidemiology and StatisticS (CRESS), Service de Psychiatrie de l'adulte, AP-HP, H&#xf4;pital H&#xf4;tel-Dieu, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robineau</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Service Universitaire des Maladies Infectieuses, Centre Hospitalier Gustave Dron, Tourcoing, France; Sorbonne Universit&#xe9;, INSERM, Institut Pierre Louis d'Epid&#xe9;miologie et de Sant&#xe9; Publique, IPLESP, UMR-S 1136, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steichen</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, INSERM, Institut Pierre Louis d'Epid&#xe9;miologie et de Sant&#xe9; Publique, IPLESP, UMR-S 1136, Paris, France; AP-HP, H&#xf4;pital Tenon, Service de M&#xe9;decine Interne, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makovski</LastName><ForeName>Tatjana T</ForeName><Initials>TT</Initials><AffiliationInfo><Affiliation>Department of Non-Communicable Diseases and Injuries, French Public Health Agency (Sant&#xe9; Publique France), Saint-Maurice, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Microbiol Infect</MedlineTA><NlmUniqueID>9516420</NlmUniqueID><ISSNLinking>1198-743X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000091569" MajorTopicYN="N">Sociodemographic Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Prevalence</Keyword><Keyword MajorTopicYN="N">Public health</Keyword><Keyword MajorTopicYN="N">Surveillance</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>3</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>11</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>26</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>25</Day><Hour>20</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38527615</ArticleId><ArticleId IdType="doi">10.1016/j.cmi.2024.03.020</ArticleId><ArticleId IdType="pii">S1198-743X(24)00150-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>